Ivanov Andrei, Beers Stephen A, Walshe Claire A, Honeychurch Jamie, Alduaij Waleed, Cox Kerry L, Potter Kathleen N, Murray Stephen, Chan Claude H T, Klymenko Tetyana, Erenpreisa Jekaterina, Glennie Martin J, Illidge Tim M, Cragg Mark S
CRUK Paterson Institute for Cancer Research, School of Cancer and Imaging Sciences, School of Medicine, University of Manchester, Manchester, United Kingdom.
J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.
mAbs are becoming increasingly utilized in the treatment of lymphoid disorders. Although Fc-FcgammaR interactions are thought to account for much of their therapeutic effect, this does not explain why certain mAb specificities are more potent than others. An additional effector mechanism underlying the action of some mAbs is the direct induction of cell death. Previously, we demonstrated that certain CD20-specific mAbs (which we termed type II mAbs) evoke a nonapoptotic mode of cell death that appears to be linked with the induction of homotypic adhesion. Here, we reveal that peripheral relocalization of actin is critical for the adhesion and cell death induced by both the type II CD20-specific mAb tositumomab and an HLA-DR-specific mAb in both human lymphoma cell lines and primary chronic lymphocytic leukemia cells. The cell death elicited was rapid, nonapoptotic, nonautophagic, and dependent on the integrity of plasma membrane cholesterol and activation of the V-type ATPase. This cytoplasmic cell death involved lysosomes, which swelled and then dispersed their contents, including cathepsin B, into the cytoplasm and surrounding environment. The resulting loss of plasma membrane integrity occurred independently of caspases and was not controlled by Bcl-2. These experiments provide what we believe to be new insights into the mechanisms by which 2 clinically relevant mAbs elicit cell death and show that this homotypic adhesion-related cell death occurs through a lysosome-dependent pathway.
单克隆抗体(mAbs)在淋巴系统疾病治疗中的应用日益广泛。尽管Fc-FcγR相互作用被认为是其治疗效果的主要原因,但这并不能解释为何某些单克隆抗体的特异性比其他抗体更强。某些单克隆抗体作用的另一种效应机制是直接诱导细胞死亡。此前,我们证明某些CD20特异性单克隆抗体(我们称之为II型单克隆抗体)可引发一种非凋亡性细胞死亡模式,这种模式似乎与同型黏附的诱导有关。在此,我们发现,在人淋巴瘤细胞系和原发性慢性淋巴细胞白血病细胞中,肌动蛋白的外周重新定位对于II型CD20特异性单克隆抗体托西莫单抗和HLA-DR特异性单克隆抗体诱导的黏附和细胞死亡至关重要。引发的细胞死亡迅速,是非凋亡性、非自噬性的,且依赖于质膜胆固醇的完整性和V型ATP酶的激活。这种细胞质细胞死亡涉及溶酶体,溶酶体肿胀,然后将其内容物(包括组织蛋白酶B)分散到细胞质和周围环境中。由此导致的质膜完整性丧失独立于半胱天冬酶发生,且不受Bcl-2的控制。这些实验为我们认为的两种临床相关单克隆抗体引发细胞死亡的机制提供了新的见解,并表明这种同型黏附相关的细胞死亡通过溶酶体依赖性途径发生。